AYME FROMETA: Open Payments
NPI 1669600995 · NEWARK, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$927 in 64 payments from 9 companies in 2025. Trend: 2023 $389 · 2024 $813 · 2025 $927
Food & beverage: $927
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 19 | $290 |
| ABBVIE INC. | 22 | $236 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $102 |
| Teva Pharmaceuticals USA, Inc. | 5 | $94 |
| E.R. Squibb & Sons, L.L.C. | 5 | $86 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $52 |
| Axsome Therapeutics, Inc. | 2 | $35 |
| Lundbeck LLC | 1 | $17 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
Products named: REXULTI, VRAYLAR, TRINTELLIX, UZEDY, COBENFY, CAPLYTA, ABILIFY ASIMTUFII, Auvelity.
Industry payments across NJ — which companies pay providers there.
